ReviewJournal of gastric cancer2023
Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer.
Review in Journal of gastric cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Perioperative versus adjuvant chemotherapy for resectable gastric cancer: a meta-analysis of randomized controlled trials.Frontiers in oncology · 2025Pooled it
- Artificial intelligence and machine learning-driven advancements in gastrointestinal cancer: Paving the way for precision medicine.World journal of gastroenterology · 2026Review
- Analysis of the risk of metachronous colorectal cancer and long-term prognosis in patients following gastrectomy for gastric cancer.Scientific reports · 2025Article
- Reply: Comment on Rethinking Neoadjuvant Therapy: A Critical Evaluation of Exclusion Criteria in Gastric Cancer Surgery Studies.Journal of gastric cancer · 2025Article
- Evolution of HER2 expression after neoadjuvant therapy in locally advanced gastric cancer.iScience · 2025Article
- Reply: Are the Findings Reliable? A Critical Evaluation of "Lifestyle Behaviors in Patients With Gastric Cancer".Journal of gastric cancer · 2025Article
- Efficacy and safety of neoadjuvant bevacizumab plus chemotherapy in locally advanced gastric cancer patients: a retrospective, comparative study.World journal of surgical oncology · 2025Article
- Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer.Turkish journal of medical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Presently, surgery is the only treatment approach for gastric cancer and improving the prognosis of locally advanced gastric cancer is one of the key factors in promoting gastric cancer survival benefit. The MAGIC study was the first to demonstrate the efficacy of neoadjuvant chemotherapy (NAC) in European countries. In recent years, several clinical trials have provided evidence for the use of NAC in Asian patients with locally advanced gastric cancer. However, clinical practice guidelines vary between Asian and non-Asian populations. Optimal NAC regimens, proper target populations, and predictors of NAC outcomes in Asian patients are still under investigation. Herein, we summarized the current progress in the administration of NAC in Asian patients with gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.